33-Breast metastatic trastuzumab three weekly

In 2006, trastuzumab plus chemotherapy was approved to treat patients after their HER2-overexpressing breast tumors were surgically removed

Trastuzumab exerts an antitumour activity and is used in the treatment of HER2-positive breast cancer HER2 protein overexpression is observed in 20%-30% of

trastuzumab Trastuzumab deruxtecan provides durable benefits to patients with heavily pretreated HER2

trastuzumab Self-Care Tips: · Drink at least two to three quarts of fluid every 24 hours, unless you are instructed otherwise · Trastuzumab causes little nausea · You may